“Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma”. Nature Genetics5 (3): 230–5. (November 1993). doi:10.1038/ng1193-230. PMID8275086.
“Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B”. The Journal of Biological Chemistry274 (24): 17179–83. (June 1999). doi:10.1074/jbc.274.24.17179. PMID10358075.
“Phosphorylation of serine 256 by protein kinase B disrupts transactivation by FKHR and mediates effects of insulin on insulin-like growth factor-binding protein-1 promoter activity through a conserved insulin response sequence”. The Journal of Biological Chemistry274 (24): 17184–92. (June 1999). doi:10.1074/jbc.274.24.17184. PMID10358076.
“The forkhead transcription factor Foxo1: a possible link between obesity and insulin resistance”. Molecular Cell11 (1): 6–8. (January 2003). doi:10.1016/S1097-2765(03)00003-0. PMID12535515.
“FOXO1 represses peroxisome proliferator-activated receptor-gamma1 and -gamma2 gene promoters in primary adipocytes. A novel paradigm to increase insulin sensitivity”. The Journal of Biological Chemistry281 (29): 19881–91. (July 2006). doi:10.1074/jbc.M600320200. PMID16670091.
“Discovery of novel forkhead box O1 inhibitors for treating type 2 diabetes: improvement of fasting glycemia in diabetic db/db mice”. Molecular Pharmacology78 (5): 961–70. (November 2010). doi:10.1124/mol.110.065714. PMID20736318.
“FoxO1 is required for the regulation of preproglucagon gene expression by insulin in pancreatic alphaTC1-9 cells”. The Journal of Biological Chemistry281 (51): 39358–69. (December 2006). doi:10.1074/jbc.M605022200. PMID17062568.
“FOXO transcription factors in the regulatory networks of longevity”. Journal of Biochemistry141 (6): 769–74. (June 2007). doi:10.1093/jb/mvm104. PMID17569704.
“Death versus dedifferentiation: The molecular bases of beta cell mass reduction in type 2 diabetes”. Seminars in Cell and Developmental Biology103: 76–82. (2019). doi:10.1016/j.semcdb.2019.12.002. PMID31831356.
“Regulation of insulin action and pancreatic beta-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1”. Nature Genetics32 (2): 245–53. (October 2002). doi:10.1038/ng890. PMID12219087.
“Molecular signaling mechanisms of renal gluconeogenesis in nondiabetic and diabetic conditions”. Journal of Cellular Physiology234 (6): 8134–8151. (2019). doi:10.1002/jcp.27598. PMID30370538.
“Ligand-dependent interaction of estrogen receptor-alpha with members of the forkhead transcription factor family”. The Journal of Biological Chemistry276 (36): 33554–60. (September 2001). doi:10.1074/jbc.M105555200. PMID11435445.
“Interaction of FoxO1 and TSC2 induces insulin resistance through activation of the mammalian target of rapamycin/p70 S6K pathway”. The Journal of Biological Chemistry281 (52): 40242–51. (December 2006). doi:10.1074/jbc.M608116200. PMID17077083.
“Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma”. Nature Genetics5 (3): 230–5. (November 1993). doi:10.1038/ng1193-230. PMID8275086.
“Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B”. The Journal of Biological Chemistry274 (24): 17179–83. (June 1999). doi:10.1074/jbc.274.24.17179. PMID10358075.
“Phosphorylation of serine 256 by protein kinase B disrupts transactivation by FKHR and mediates effects of insulin on insulin-like growth factor-binding protein-1 promoter activity through a conserved insulin response sequence”. The Journal of Biological Chemistry274 (24): 17184–92. (June 1999). doi:10.1074/jbc.274.24.17184. PMID10358076.
“The forkhead transcription factor Foxo1: a possible link between obesity and insulin resistance”. Molecular Cell11 (1): 6–8. (January 2003). doi:10.1016/S1097-2765(03)00003-0. PMID12535515.
“FOXO1 represses peroxisome proliferator-activated receptor-gamma1 and -gamma2 gene promoters in primary adipocytes. A novel paradigm to increase insulin sensitivity”. The Journal of Biological Chemistry281 (29): 19881–91. (July 2006). doi:10.1074/jbc.M600320200. PMID16670091.
“Discovery of novel forkhead box O1 inhibitors for treating type 2 diabetes: improvement of fasting glycemia in diabetic db/db mice”. Molecular Pharmacology78 (5): 961–70. (November 2010). doi:10.1124/mol.110.065714. PMID20736318.
“FoxO1 is required for the regulation of preproglucagon gene expression by insulin in pancreatic alphaTC1-9 cells”. The Journal of Biological Chemistry281 (51): 39358–69. (December 2006). doi:10.1074/jbc.M605022200. PMID17062568.
“FOXO transcription factors in the regulatory networks of longevity”. Journal of Biochemistry141 (6): 769–74. (June 2007). doi:10.1093/jb/mvm104. PMID17569704.
“Death versus dedifferentiation: The molecular bases of beta cell mass reduction in type 2 diabetes”. Seminars in Cell and Developmental Biology103: 76–82. (2019). doi:10.1016/j.semcdb.2019.12.002. PMID31831356.
“Regulation of insulin action and pancreatic beta-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1”. Nature Genetics32 (2): 245–53. (October 2002). doi:10.1038/ng890. PMID12219087.
“Molecular signaling mechanisms of renal gluconeogenesis in nondiabetic and diabetic conditions”. Journal of Cellular Physiology234 (6): 8134–8151. (2019). doi:10.1002/jcp.27598. PMID30370538.
“Ligand-dependent interaction of estrogen receptor-alpha with members of the forkhead transcription factor family”. The Journal of Biological Chemistry276 (36): 33554–60. (September 2001). doi:10.1074/jbc.M105555200. PMID11435445.
“Interaction of FoxO1 and TSC2 induces insulin resistance through activation of the mammalian target of rapamycin/p70 S6K pathway”. The Journal of Biological Chemistry281 (52): 40242–51. (December 2006). doi:10.1074/jbc.M608116200. PMID17077083.